These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 7516657)

  • 1. Enhancement of antineoplastic activity of 5-fluorouracil in mice bearing colon 38 tumor by (6R)5,10-dideazatetrahydrofolic acid.
    Pizzorno G; Davis SJ; Hartigan DJ; Russello O
    Biochem Pharmacol; 1994 Jun; 47(11):1981-8. PubMed ID: 7516657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of HL-60 leukemia cell differentiation by the novel antifolate 5,10-dideazatetrahydrofolic acid.
    Sokoloski JA; Beardsley GP; Sartorelli AC
    Cancer Res; 1989 Sep; 49(17):4824-8. PubMed ID: 2758415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of HL-60 leukemia cell differentiation by tetrahydrofolate inhibitors of de novo purine nucleotide biosynthesis.
    Sokoloski JA; Beardsley GP; Sartorelli AC
    Cancer Chemother Pharmacol; 1991; 28(1):39-44. PubMed ID: 2040032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol.
    Mendelsohn LG; Shih C; Schultz RM; Worzalla JF
    Invest New Drugs; 1996; 14(3):287-94. PubMed ID: 8958184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM.
    Pizzorno G; Moroson BA; Cashmore AR; Russello O; Mayer JR; Galivan J; Bunni MA; Priest DG; Beardsley GP
    Cancer Res; 1995 Feb; 55(3):566-73. PubMed ID: 7834626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tight binding of folate substrates and inhibitors to recombinant mouse glycinamide ribonucleotide formyltransferase.
    Sanghani SP; Moran RG
    Biochemistry; 1997 Aug; 36(34):10506-16. PubMed ID: 9265631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for a relationship between intracellular GTP levels and the induction of HL-60 leukemia cell differentiation by 5,10-dideazatetrahydrofolic acid (DDATHF).
    Sokoloski JA; Pizzorno G; Beardsley GP; Sartorelli AC
    Oncol Res; 1993; 5(8):293-9. PubMed ID: 8012061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifolates targeting purine synthesis allow entry of tumor cells into S phase regardless of p53 function.
    Bronder JL; Moran RG
    Cancer Res; 2002 Sep; 62(18):5236-41. PubMed ID: 12234990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells.
    Smith SG; Lehman NL; Moran RG
    Cancer Res; 1993 Dec; 53(23):5697-706. PubMed ID: 8242626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural features of 5,10-dideaza-5,6,7,8-tetrahydrofolate that determine inhibition of mammalian glycinamide ribonucleotide formyltransferase.
    Baldwin SW; Tse A; Gossett LS; Taylor EC; Rosowsky A; Shih C; Moran RG
    Biochemistry; 1991 Feb; 30(7):1997-2006. PubMed ID: 1993209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 6S- and 6R-diastereomers of 5, 10-dideaza-5, 6, 7, 8-tetrahydrofolate are equiactive inhibitors of de novo purine synthesis.
    Moran RG; Baldwin SW; Taylor EC; Shih C
    J Biol Chem; 1989 Dec; 264(35):21047-51. PubMed ID: 2592365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 10-Formyl-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid (10-formyl-DDACTHF): a potent cytotoxic agent acting by selective inhibition of human GAR Tfase and the de novo purine biosynthetic pathway.
    Marsilje TH; Labroli MA; Hedrick MP; Jin Q; Desharnais J; Baker SJ; Gooljarsingh LT; Ramcharan J; Tavassoli A; Zhang Y; Wilson IA; Beardsley GP; Benkovic SJ; Boger DL
    Bioorg Med Chem; 2002 Aug; 10(8):2739-49. PubMed ID: 12057663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (6R)-5,10-Dideaza-5,6,7,8-tetrahydrofolic acid effects on nucleotide metabolism in CCRF-CEM human T-lymphoblast leukemia cells.
    Pizzorno G; Moroson BA; Cashmore AR; Beardsley GP
    Cancer Res; 1991 May; 51(9):2291-5. PubMed ID: 1707749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo antitumor activity and metabolism of a series of 5-deazaacyclotetrahydrofolate (5-DACTHF) analogues.
    Mullin RJ; Keith BR; Bigham EC; Duch DS; Ferone R; Heath LS; Singer S; Waters KA; Wilson HR
    Biochem Pharmacol; 1992 Apr; 43(7):1627-34. PubMed ID: 1567484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis.
    Beardsley GP; Moroson BA; Taylor EC; Moran RG
    J Biol Chem; 1989 Jan; 264(1):328-33. PubMed ID: 2909524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracellular metabolism of 5,10-dideazatetrahydrofolic acid in human leukemia cell lines.
    Pizzorno G; Sokoloski JA; Cashmore AR; Moroson BA; Cross AD; Beardsley GP
    Mol Pharmacol; 1991 Jan; 39(1):85-9. PubMed ID: 1702876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluation of 10-methanesulfonyl-DDACTHF, 10-methanesulfonyl-5-DACTHF, and 10-methylthio-DDACTHF as potent inhibitors of GAR Tfase and the de novo purine biosynthetic pathway.
    Cheng H; Chong Y; Hwang I; Tavassoli A; Zhang Y; Wilson IA; Benkovic SJ; Boger DL
    Bioorg Med Chem; 2005 May; 13(10):3577-85. PubMed ID: 15848770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of the disparate antitumor activities of (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolate and methotrexate toward human lymphoblastic leukemia cells, characterized by severely impaired antifolate membrane transport.
    Matherly LH; Angeles SM; McGuire JJ
    Biochem Pharmacol; 1993 Dec; 46(12):2185-95. PubMed ID: 7506026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.
    Laohavinij S; Wedge SR; Lind MJ; Bailey N; Humphreys A; Proctor M; Chapman F; Simmons D; Oakley A; Robson L; Gumbrell L; Taylor GA; Thomas HD; Boddy AV; Newell DR; Calvert AH
    Invest New Drugs; 1996; 14(3):325-35. PubMed ID: 8958188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors.
    Habeck LL; Leitner TA; Shackelford KA; Gossett LS; Schultz RM; Andis SL; Shih C; Grindey GB; Mendelsohn LG
    Cancer Res; 1994 Feb; 54(4):1021-6. PubMed ID: 8313357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.